Tang, Shenghui

Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody

Maher, V. E., Fernandes, L. L., Weinstock, C., Tang, S., Agarwal, S., Brave, M., Ning, Y.-M., Singh, H., Suzman, D., Xu, J., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 331

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., et al. (2023) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 255

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 180

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 105

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 99

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., et al. (2024) · Journal of Clinical Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 86